Skip to main content

Yarema, Kevin

Associate Professor
Som Biomedical Engineering

Smith Bldg 5029
(410) 614-6835

Jump to:


  • Bachelor of Science 1988, Walla Walla University
  • 2019 - Present:  Associate Professor, SOM Oncology Center


Journal Articles
  • Saeui CT, Cho KC, Dharmarha V, Nairn AV, Galizzi M, Shah SR, Gowda P, Park M, Austin M, Clarke A, Cai E, Buettner MJ, Ariss R, Moremen KW, Zhang H, Yarema KJ (2020).  Cell Line-, Protein-, and Sialoglycosite-Specific Control of Flux-Based Sialylation in Human Breast Cells: Implications for Cancer Progression.  Frontiers in Chemistry.  8.
  • Agatemor C, Buettner MJ, Ariss R, Muthiah K, Saeui CT, Yarema KJ (2019).  Exploiting metabolic glycoengineering to advance healthcare.  Nature Reviews Chemistry.  3(10).  605-620.
  • Wang Q, Chung CY, Yang W, Yang G, Chough S, Chen Y, Yin B, Bhattacharya R, Hu Y, Saeui CT, Yarema KJ, Betenbaugh MJ, Zhang H (2019).  Combining Butyrated ManNAc with Glycoengineered CHO Cells Improves EPO Glycan Quality and Production.  Biotechnology Journal.  14(4).
  • Buettner MJ, Shah SR, Saeui CT, Ariss R, Yarema KJ (2018).  Improving immunotherapy through glycodesign.  Frontiers in Immunology.  9(NOV).
  • Yin B, Wang Q, Chung CY, Ren X, Bhattacharya R, Yarema KJ, Betenbaugh MJ (2018).  Butyrated ManNAc analog improves protein expression in Chinese hamster ovary cells.  Biotechnology and Bioengineering.  115(6).  1531-1541.
  • Saeui CT, Nairn AV, Galizzi M, Douville C, Gowda P, Park M, Dharmarha V, Shah SR, Clarke A, Austin M, Moremen KW, Yarema KJ (2018).  Integration of genetic and metabolic features related to sialic acid metabolism distinguishes human breast cell subtypes.  PLoS ONE.  13(5).
  • Meyer RA, Mathew MP, Ben-Akiva E, Sunshine JC, Shmueli RB, Ren Q, Yarema KJ, Green JJ (2018).  Anisotropic biodegradable lipid coated particles for spatially dynamic protein presentation.  Acta Biomaterialia.  72.  228-238.
  • Saeui CT, Liu L, Urias E, Morrissette-Mcalmon J, Bhattacharya R, Yarema KJ (2018).  Pharmacological, Physiochemical, and Drug-Relevant Biological Properties of Short Chain Fatty Acid Hexosamine Analogues Used in Metabolic Glycoengineering.  Molecular Pharmaceutics.  15(3).  705-720.
  • Kim H, Shin K, Park OK, Choi D, Kim HD, Baik S, Lee SH, Kwon SH, Yarema KJ, Hong J, Hyeon T, Hwang NS (2018).  General and Facile Coating of Single Cells via Mild Reduction.  Journal of the American Chemical Society.  140(4).  1199-1202.
  • Yin B, Wang Q, Chung CY, Bhattacharya R, Ren X, Tang J, Yarema KJ, Betenbaugh MJ (2017).  A novel sugar analog enhances sialic acid production and biotherapeutic sialylation in CHO cells.  Biotechnology and Bioengineering.  114(8).  1899-1902.
  • Mathew MP, Tan E, Labonte JW, Shah S, Saeui CT, Liu L, Bhattacharya R, Bovonratwet P, Gray JJ, Yarema KJ (2017).  Glycoengineering of Esterase Activity through Metabolic Flux-Based Modulation of Sialic Acid.  ChemBioChem.  18(13).  1204-1215.
  • Song Y, Kilburn D, Song JH, Cheng Y, Saeui CT, Cheung DG, Croce CM, Yarema KJ, Meltzer SJ, Liu KJ, Wang TH (2017).  Determination of absolute expression profiles using multiplexed miRNA analysis.  PLoS ONE.  12(7).
  • Badr HA, AlSadek DMM, El-Houseini ME, Saeui CT, Mathew MP, Yarema KJ, Ahmed H (2017).  Harnessing cancer cell metabolism for theranostic applications using metabolic glycoengineering of sialic acid in breast cancer as a pioneering example.  Biomaterials.  116.  158-173.
  • Kim C, Shores L, Guo Q, Aly A, Jeon OH, Kim DH, Bernstein N, Bhattacharya R, Chae JJ, Yarema KJ, Elisseeff JH (2016).  Electrospun Microfiber Scaffolds with Anti-Inflammatory Tributanoylated N-Acetyl-d-Glucosamine Promote Cartilage Regeneration.  Tissue Engineering - Part A.  22(7-8).  689-697.
  • Kim C, Jeon OH, Kim DH, Chae JJ, Shores L, Bernstein N, Bhattacharya R, Coburn JM, Yarema KJ, Elisseeff JH (2016).  Local delivery of a carbohydrate analog for reducing arthritic inflammation and rebuilding cartilage.  Biomaterials.  83.  93-101.
  • Mathew MP, Tan E, Saeui CT, Bovonratwet P, Sklar S, Bhattacharya R, Yarema KJ (2016).  Metabolic flux-driven sialylation alters internalization, recycling, and drug sensitivity of the epidermal growth factor receptor (EGFR) in SW1990 pancreatic cancer cells.  Oncotarget.  7(41).  66491-66511.
  • Badr HA, AlSadek DMM, Mathew MP, Li CZ, Djansugurova LB, Yarema KJ, Ahmed H (2015).  Lectin staining and Western blot data showing differential sialylation of nutrient-deprived cancer cells to sialic acid supplementation.  Data in Brief.  5.  481-488.
  • Badr HA, AlSadek DMM, Mathew MP, Li CZ, Djansugurova LB, Yarema KJ, Ahmed H (2015).  Nutrient-deprived cancer cells preferentially use sialic acid to maintain cell surface glycosylation.  Biomaterials.  70.  23-36.
  • Saeui CT, Urias E, Liu L, Mathew MP, Yarema KJ (2015).  Metabolic glycoengineering bacteria for therapeutic, recombinant protein, and metabolite production applications.  Glycoconjugate Journal.  32(7).  425-441.
  • Mishra S, Bedja D, Amuzie C, Foss CA, Pomper MG, Bhattacharya R, Yarema KJ, Chatterjee S (2015).  Improved intervention of atherosclerosis and cardiac hypertrophy through biodegradable polymer-encapsulated delivery of glycosphingolipid inhibitor.  Biomaterials.  64.  125-135.
  • Mathew MP, Tan E, Saeui CT, Bovonratwet P, Liu L, Bhattacharya R, Yarema KJ (2015).  Metabolic glycoengineering sensitizes drug-resistant pancreatic cancer cells to tyrosine kinase inhibitors erlotinib and gefitinib.  Bioorganic and Medicinal Chemistry Letters.  25(6).  1223-1227.
  • Tian Y, Almaraz RT, Choi CH, Li QK, Saeui C, Li D, Shah P, Bhattacharya R, Yarema KJ, Zhang H (2015).  Identification of sialylated glycoproteins from metabolically oligosaccharide engineered pancreatic cells.  Clinical Proteomics.  12(1).
  • Gibson M, Li H, Coburn J, Moroni L, Nahas Z, Bingham C, Yarema K, Elisseeff J (2014).  Intra-articular delivery of glucosamine for treatment of experimental osteoarthritis created by a medial meniscectomy in a rat model.  Journal of Orthopaedic Research.  32(2).  302-309.
  • Du J, Tan E, Kim HJ, Zhang A, Bhattacharya R, Yarema KJ (2014).  Comparative evaluation of chitosan, cellulose acetate, and polyethersulfone nanofiber scaffolds for neural differentiation.  Carbohydrate Polymers.  99.  483-490.
  • Coburn JM, Wo L, Bernstein N, Bhattacharya R, Aich U, Bingham CO, Yarema KJ, Elisseeff JH (2013).  Short-chain fatty acid-modified hexosamine for tissue-engineering osteoarthritic cartilage.  Tissue Engineering - Part A.  19(17-18).  2035-2044.
  • Shah P, Yang S, Sun S, Aiyetan P, Yarema KJ, Zhang H (2013).  Mass spectrometric analysis of sialylated glycans with use of solid-phase labeling of sialic acids.  Analytical Chemistry.  85(7).  3606-3613.
  • Coburn JM, Bernstein N, Bhattacharya R, Aich U, Yarema KJ, Elisseeff JH (2013).  Differential Response of Chondrocytes and Chondrogenic-Induced Mesenchymal Stem Cells to C1-OH Tributanoylated N-Acetylhexosamines.  PLoS ONE.  8(3).
  • Bennun SV, Yarema KJ, Betenbaugh MJ, Krambeck FJ (2013).  Integration of the Transcriptome and Glycome for Identification of Glycan Cell Signatures.  PLoS Computational Biology.  9(1).
  • Mathew MP, Tan E, Shah S, Bhattacharya R, Adam Meledeo M, Huang J, Espinoza FA, Yarema KJ (2012).  Extracellular and intracellular esterase processing of SCFA-hexosamine analogs: Implications for metabolic glycoengineering and drug delivery.  Bioorganic and Medicinal Chemistry Letters.  22(22).  6929-6933.
  • Almaraz RT, Tian Y, Bhattarcharya R, Tan E, Chen SH, Dallas MR, Chen L, Zhang Z, Zhang H, Konstantopoulos K, Yarema KJ (2012).  Metabolic flux increases glycoprotein sialylation: Implications for cell adhesion and cancer metastasis.  Molecular and Cellular Proteomics.  11(7).
  • Almaraz RT, Aich U, Khanna HS, Tan E, Bhattacharya R, Shah S, Yarema KJ (2012).  Metabolic oligosaccharide engineering with N-Acyl functionalized ManNAc analogs: Cytotoxicity, metabolic flux, and glycan-display considerations.  Biotechnology and Bioengineering.  109(4).  992-1006.
  • Almaraz RT, Mathew MP, Tan E, Yarema KJ (2012).  Metabolic oligosaccharide engineering: Implications for selectin-mediated adhesion and leukocyte extravasation.  Annals of Biomedical Engineering.  40(4).  806-815.
  • Granell AEVB, Palter KB, Akan I, Aich U, Yarema KJ, Betenbaugh MJ, Thornhill WB, Recio-Pinto E (2011).  Dm SAS is required for sialic acid biosynthesis in cultured Drosophila third instar larvae CNS neurons.  ACS Chemical Biology.  6(11).  1287-1295.
  • Du J, Che PL, Aich U, Tan E, Kim HJ, Sampathkumar SG, Yarema KJ (2011).  Deciphering glycan linkages involved in Jurkat cell interactions with gold-coated nanofibers via sugar-displayed thiols.  Bioorganic and Medicinal Chemistry Letters.  21(17).  4980-4984.
  • Du J, Che PL, Wang ZY, Aich U, Yarema KJ (2011).  Designing a binding interface for control of cancer cell adhesion via 3D topography and metabolic oligosaccharide engineering.  Biomaterials.  32(23).  5427-5437.
  • Lim SH, Liu XY, Song H, Yarema KJ, Mao HQ (2010).  The effect of nanofiber-guided cell alignment on the preferential differentiation of neural stem cells.  Biomaterials.  31(34).  9031-9039.
  • Wang Z, Che PL, Du J, Ha B, Yarema KJ (2010).  Static Magnetic Field Exposure Reproduces Cellular Effects of the Parkinson's Disease Drug Candidate ZM241385.  PLoS ONE.  5(11).
  • Du J, Yarema KJ (2010).  Carbohydrate engineered cells for regenerative medicine.  Advanced Drug Delivery Reviews.  62(7-8).  671-682.
  • Aich U, Meledeo MA, Sampathkumar SG, Fu J, Jones MB, Weier CA, Chung SY, Tang BC, Yang M, Hanes J, Yarema KJ (2010).  Development of delivery methods for carbohydrate-based drugs: Controlled release of biologically-active short chain fatty acid-hexosamine analogs.  Glycoconjugate Journal.  27(4).  445-459.
  • Wang Z, Du J, Che PL, Meledeo MA, Yarema KJ (2009).  Hexosamine analogs: from metabolic glycoengineering to drug discovery.  Current Opinion in Chemical Biology.  13(5-6).  565-572.
  • Du J, Meledeo MA, Wang Z, Khanna HS, Paruchuri VDP, Yarema KJ (2009).  Metabolic glycoengineering: Sialic acid and beyond.  Glycobiology.  19(12).  1382-1401.
  • Krambeck FJ, Bennun SV, Narang S, Choi S, Yarema KJ, Betenbaugh MJ (2009).  A mathematical model to derive N-glycan structures and cellular enzyme activities from mass spectrometric data.  Glycobiology.  19(11).  1163-1175.
  • Wang Z, Sarje A, Che PL, Yarema KJ (2009).  Moderate strength (0.23-0.28 T) static magnetic fields (SMF) modulate signaling and differentiation in human embryonic cells.  BMC Genomics.  10.
  • Elmouelhi N, Aich U, Paruchuri VDP, Meledeo MA, Campbell CT, Wang JJ, SriNivas R, Khanna HS, Yarema KJ (2009).  Hexosamine template. A platform for modulating gene expression and for sugar-based drug discovery.  Journal of Medicinal Chemistry.  52(8).  2515-2530.
  • Campbell CT, Aich U, Weier CA, Wang JJ, Choi SS, Wen MM, Maisel K, Sampathkumar SG, Yarema KJ (2008).  Targeting pro-invasive oncogenes with short chain fatty acid-hexosamine analogues inhibits the mobility of metastatic MDA-MB-231 breast cancer cells.  Journal of Medicinal Chemistry.  51(24).  8135-8147.
  • Aich U, Campbell CT, Elmouelhi N, Weier CA, Sampathkumar SG, Choi SS, Yarema KJ (2008).  Regioisomeric SCFA attachment to hexosamines separates metabolic flux from cytotoxicity and MUC1 suppression.  ACS Chemical Biology.  3(4).  230-240.
  • Kim EJ, Shin HY, Park S, Sung D, Jon S, Sampathkumar SG, Yarema KJ, Choi SY, Kim K (2008).  Electrochemically active, anti-biofouling polymer adlayers on indium-tin-oxide electrodes.  Chemical Communications.  (30).  3543-3545.
  • Daubeuf S, Aucher A, Sampathkumar SG, Preville X, Yarema KJ, Hudrisier D (2007).  Chemical labels metabolically installed into the glycoconjugates of the target cell surface can be used to track lymphocyte/target cell interplay via trogocytosis: Comparisons with lipophilic dyes and biotin.  Immunological Investigations.  36(5-6).  687-712.
  • Campbell CT, Sampathkumar SG, Yarema KJ (2007).  Metabolic oligosaccharide engineering: Perspectives, applications, and future directions.  Molecular BioSystems.  3(3).  187-194.
  • Faure C, Chalazonitis A, Rhéaume C, Bouchard G, Sampathkumar SG, Yarema KJ, Gershon MD (2007).  Gangliogenesis in the enteric nervous system: Roles of the polysialylation of the neural cell adhesion molecule and its regulation by bone morphogenetic protein-4.  Developmental Dynamics.  236(1).  44-59.
  • Varghese S, Theprungsirikul P, Sahani S, Hwang N, Yarema KJ, Elisseeff JH (2007).  Glucosamine modulates chondrocyte proliferation, matrix synthesis, and gene expression.  Osteoarthritis and Cartilage.  15(1).  59-68.
  • Sampathkumar SG, Campbell CT, Weier C, Yarema KJ (2006).  Short-chain fatty acid-hexosamine cancer prodrugs: The sugar matters!.  Drugs of the Future.  31(12).  1099-1116.
  • Sampathkumar SG, Jones MB, Meledeo MA, Campbell CT, Choi SS, Hida K, Gomutputra P, Sheh A, Gilmartin T, Head SR, Yarema KJ (2006).  Targeting Glycosylation Pathways and the Cell Cycle: Sugar-Dependent Activity of Butyrate-Carbohydrate Cancer Prodrugs.  Chemistry and Biology.  13(12).  1265-1275.
  • Sampathkumar SG, Li AV, Yarema KJ (2006).  Synthesis of non-natural ManNAc analogs for the expression of thiols on cell-surface sialic acids.  Nature Protocols.  1(5).  2377-2385.
  • Sampathkumar SG, Jones MB, Yarema KJ (2006).  Metabolic expression of thiol-derivatized sialic acids on the cell surface and their quantitative estimation by flow cytometry.  Nature Protocols.  1(4).  1840-1851.
  • Wang Z, Sun Z, Li AV, Yarema KJ (2006).  Roles for UDP-GlcNAc 2-epimerase/ManNAc 6-kinase outside of sialic acid biosynthesis: Modulation of sialyltransferase and BiP expression, GM3 and GD3 biosynthesis, proliferation, and apoptosis, and ERK1/2 phosphorylation.  Journal of Biological Chemistry.  281(37).  27016-27028.
  • Sampathkumar SG, Li A, Yarema KJ (2006).  Sialic acid and the central nervous system: Perspectives on biological functions, detection, imaging methods and manipulation.  CNS and Neurological Disorders - Drug Targets.  5(4).  425-440.
  • Sampathkumar SG, Li AV, Jones MB, Sun Z, Yarema KJ (2006).  Metabolic installation of thiols into sialic acid modulates adhesion and stem cell biology.  Nature Chemical Biology.  2(3).  149-152.
  • Campbell CT, Yarema KJ (2005).  Large-scale approaches for glycobiology.  Genome Biology.  6(11).
  • Salama I, Hinderlich S, Shlomai Z, Eisenberg I, Krause S, Yarema K, Argov Z, Lochmuller H, Reutter W, Dabby R, Sadeh M, Ben-Bassat H, Mitrani-Rosenbaum S (2005).  No overall hyposialylation in hereditary inclusion body myopathy myoblasts carrying the homozygous M712T GNE mutation.  Biochemical and Biophysical Research Communications.  328(1).  221-226.
  • Sun Z, Yarema KJ (2005).  Introduction.  Handbook of Carbohydrate Engineering.  v-xxiv.
  • Yarema KJ, Sun Z (2005).  A photochemical snapshot of CD22 binding.  Nature Chemical Biology.  1(2).  69-70.
  • Eun JK, Jones MB, Jun KR, Sampathkumar SG, Yarema KJ (2004).  Establishment of N-acetylmannosamine (ManNAc) analogue-resistant cell lines as improved hosts for sialic acid engineering applications.  Biotechnology Progress.  20(6).  1674-1682.
  • Murrell MP, Yarema KJ, Levchenko A (2004).  The systems biology of glycosylation.  ChemBioChem.  5(10).  1334-1347.
  • Hinderlich S, Salama I, Eisenberg I, Potikha T, Mantey LR, Yarema KJ, Horstkorte R, Argov Z, Sadeh M, Reutter W, Mitrani-Rosenbaum S (2004).  The homozygous M712T mutation of UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase results in reduced enzyme activities but not in altered overall cellular sialylation in hereditary inclusion body myopathy.  FEBS Letters.  566(1-3).  105-109.
  • Kim EJ, Sampathkumar SG, Jones MB, Rhee JK, Baskaran G, Goon S, Yarema KJ (2004).  Characterization of the Metabolic Flux and Apoptotic Effects of O-Hydroxyl- and N-Acyl-modified N-Acetylmannosamine Analogs in Jurkat Cells.  Journal of Biological Chemistry.  279(18).  18342-18352.
  • Jones MB, Teng H, Rhee JK, Lahar N, Baskaran G, Yarema KJ (2004).  Characterization of the Cellular Uptake and Metabolic Conversion of Acetylated N-Acetylmannosamine (ManNAc) Analogues to Sialic Acids.  Biotechnology and Bioengineering.  85(4).  394-405.
  • Viswanathan K, Lawrence S, Hinderlich S, Yarema KJ, Lee YC, Betenbaugh MJ (2003).  Engineering Sialic Acid Synthetic Ability into Insect Cells: Identifying Metabolic Bottlenecks and Devising Strategies to Overcome Them.  Biochemistry.  42(51).  15215-15225.
  • Tong L, Baskaran G, Jones MB, Rhee JK, Yarema KJ (2003).  Glycosylation Changes as Markers for the Diagnosis and Treatment of Human Disease.  Biotechnology and Genetic Engineering Reviews.  20(1).  199-246.
  • Luchansky SJ, Yarema KJ, Takahashi S, Bertozzi CR (2003).  GlcNAc 2-epimerase can serve a catabolic role in sialic acid metabolism.  Journal of Biological Chemistry.  278(10).  8035-8042.
  • Jacobs CL, Goon S, Yarema KJ, Hinderlich S, Hang HC, Chai DH, Bertozzi CR (2001).  Substrate specificity of the sialic acid biosynthetic pathway.  Biochemistry.  40(43).  12864-12874.
  • Yarema KJ, Goon S, Bertozzi CR (2001).  Metabolic selection of glycosylation defects in human cells.  Nature Biotechnology.  19(6).  553-558.
  • Yarema KJ, Bertozzi CR (2001).  Characterizing glycosylation pathways.  Genome Biology.  2(5).
  • Yarema KJ (2001).  New directions in carbohydrate engineering: A metabolic substrate-based approach to modify the cell surface display of sialic acids.  BioTechniques.  31(2).  384-393.
  • Jacobs CL, Yarema KJ, Mahal LK, Nauman DA, Charters NW, Bertozzi CR (2000).  Metabolic labeling of glycoproteins with chemical tags through unnatural sialic acid biosynthesis.  Methods in Enzymology.  327.  260-275.
  • Lemieux GA, Yarema KJ, Jacobs CL, Bertozzi CR (1999).  Exploiting differences in sialoside expression for selective targeting of MRI contrast reagents.  Journal of the American Chemical Society.  121(17).  4278-4279.
  • Yarema KJ, Mahal LK, Bruehl RE, Rodriguez EC, Bertozzi CR (1998).  Metabolic delivery of ketone groups to sialic acid residues. Application to cell surface glycoform engineering.  Journal of Biological Chemistry.  273(47).  31168-31179.
  • Yarema KJ, Bertozzi CR (1998).  Chemical approaches to glycobiology and emerging carbohydrate-based therapeutic agents.  Current Opinion in Chemical Biology.  2(1).  49-61.
  • Mahal LK, Yarema KJ, Bertozzi CR (1997).  Engineering chemical reactivity on cell surfaces through oligosaccharide biosynthesis.  Science.  276(5315).  1125-1128.
  • Rink SM, Yarema KJ, Solomon MS, Paige LA, Tadayoni-Rebek BM, Essigmann JM, Croy RG (1996).  Synthesis and biological activity of DNA damaging agents that form decoy binding sites for the estrogen receptor.  Proceedings of the National Academy of Sciences of the United States of America.  93(26).  15063-15068.
  • Moggs JG, Yarema KJ, Essigmann JM, Wood RD (1996).  Analysis of incision sites produced by human cell extracts and purified proteins during nucleotide excision repair of a 1,3-intrastrand d(GpTpG)-cisplatin adduct.  Journal of Biological Chemistry.  271(12).  7177-7186.
  • Yarema KJ, Lippard SJ, Essigmann JM (1995).  Mutagenic and genotoxic effects of DNA adducts formed by the anticancer drug cis-diamminedichloroplatinum(II).  Nucleic Acids Research.  23(20).  4066-4072.
  • Yarema KJ (1995).  Comparative toxicities and mutagenicities of platinum anticancer drugs.  Drug Information Journal.  29(SUPPL.).
  • Yarema KJ, Essigmann JM (1995).  Evaluation of the genetic effects of defined dna lesions formed by dna-damaging agents.  Methods.  7(2).  133-146.
  • Yarema KJ (1995).  Comparative toxicities and mutagenicities of platinum anticancer drugs.  Therapeutic Innovation & Regulatory Science.  29(1_suppl).  1633S-1644S.
  • Yarema KJ, Wilson JM, Lippard SJ, Essigmann JM (1994).  Effects of DNA adduct structure and distribution on the mutagenicity and genotoxicity of two platinum anticancer drugs.  Journal of Molecular Biology.  236(4).  1034-1048.
  • Bradley LJN, Yarema KJ, Lippard SJ, Essigmann JM (1993).  Mutagenicity and Genotoxicity of the Major DNA Adduct of the Antitumor Drug cis-Diamminedichloroplatinum(II).  Biochemistry.  32(3).  982-988.
  • Szymkowski DE, Yarema K, Essigmann JM, Lippard SJ, Wood RD (1992).  An intrastrand d(GpG) platinum crosslink in duplex M13 DNA is refractory to repair by human cell extracts.  Proceedings of the National Academy of Sciences of the United States of America.  89(22).  10772-10776.
  • de los Santos C, Kouchakdjian M, Patel DJ, Yarema K, Basu A, Essigmann J (1991).  NMR Studies of the Exocyclic 1,N6-Ethenodeoxyadenosine Adduct (ϵdA) opposite Deoxyguanosine in a DNA Duplex. ϵdA(syn)·dG(anti) Pairing at the Lesion Site.  Biochemistry.  30(7).  1828-1835.
  • Kouchakdjian M, Patel DJ, Eisenberg M, Yarema K, Basu A, Essigmann J (1991).  NMR Studies of the Exocyclic 1,N6-Ethenodeoxyadenosine Adduct (edA) opposite Thymidine in a DNA Duplex. Nonplanar Alignment of ϵdA(anti) and dT(anti) at the Lesion Site.  Biochemistry.  30(7).  1820-1828.
  • Zhang X, Yarema K, Xu A (2017).  Biological Effects of Static Magnetic Fields.  1-220.
  • Yarema KJ (2005).  Handbook of carbohydrate engineering.  1-905.
Book Chapters
  • Du J, Yarema KJ (2014).  Cell Microencapsulation for Tissue Engineering and Regenerative Medicine.  Micro-and Nanoengineering of the Cell Surface.  215-239.
  • Alberch L, Yarema KJ (2014).  Bioconjugation Reactions in Living Cells: Development, Advances, and Applications of Glycan-Specific Technologies.  Micro-and Nanoengineering of the Cell Surface.  43-62.
  • Du J, Almaraz RT, Tan E, Yarema KJ (2013).  Metabolic glycoengineering of sialic acids.  Sialobiology: Structure, Biosynthesis and Function. Sialic Acid Glycoconjugates in Health and Disease.  476-511.
  • Meledeo MA, Paruchuri VDP, Du J, Wang Z, Yarema KJ (2011).  Mammalian Glycan Biosynthesis: Building a Template for Biological Recognition.  Carbohydrate Recognition: Biological Problems, Methods, and Applications.  1-32.
  • Atukorale PU, Choi SS, Aich U, Campbell CT, Meledeo MA, Yarema KJ (2009).  Chemical Biology of Cell Surface Oligosaccharides.  Protein Targeting with Small Molecules: Chemical Biology Techniques and Applications.  189-222.
  • Elmouelhi N, Yarema KJ (2008).  Building on what nature gave us: Engineering cell glycosylation pathways.  Biotechnology and Bioengineering.  37-74.
  • Aich U, Yarema KJ (2008).  Glycobiology and Immunology.  Carbohydrate-Based Vaccines and Immunotherapies.  1-53.
  • Chen H, Wang Z, Sun Z, Kim EJ, Yarema KJ (2005).  Mammalian glycosylation: An overview of carbohydrate biosynthesis.  Handbook of Carbohydrate Engineering.  1-48.
  • Murrell MP, Yarema KJ, Levchenko A (2005).  Computational modeling in glycosylation.  Handbook of Carbohydrate Engineering.  247-288.
  • "Short-chain fatty acid hexosamine analogs and their use in tissue engineering applications", 2019.
  • "Fatty acid carbohydrate hybrid molecules as therapeutic agents and methods thereof", 2016.
  • "Hybrid SCFA-hydroxyl-derivatized monosaccharides, methods of synthesis, and methods of treating disorders", 2015.
  • "Hybrid SCFA-hydroxyl-derivatized monosaccharides, methods of synthesis, and methods of treating disorders", 2014.
  • "Glycoconjugates and methods", 2008.
  • "Programmable genotoxic agents and uses therefor", 2007.
  • "Glycoconjugates and methods", 2005.
  • "Programmable genotoxic agents and uses therefor", 2002.
  • "Glycoconjugates and methods", 2002.
  • "Glycoconjugates and methods", 2000.
  • "Programmable genotoxic agents and uses therefor", 1999.
Back to top